Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey

被引:0
作者
Zimran, Ari [1 ,2 ]
Revel-Vilk, Shoshana [1 ,2 ]
Dinur, Tama [1 ]
Istaiti, Majdolen [1 ]
Botha, Jaco [3 ]
Lukina, Elena [4 ]
Giraldo, Pilar [5 ,6 ]
Deegan, Patrick [7 ]
vom Dahl, Stephan [8 ]
机构
[1] Shaare Zedek Med Ctr, Gaucher Unit, Eisenberg R&D Author, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[3] Takeda Pharmaceut Int AG, Zurich, Switzerland
[4] Natl Res Ctr Hematol, Dept Orphan Dis, Moscow, Russia
[5] IIS Aragon, Translat Res Unit, Zaragoza, Spain
[6] IIS Aragon, CIBER Enfermedades Raras, Zaragoza, Spain
[7] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge, England
[8] Heinrich Heine Univ, Univ Hosp, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany
关键词
Lyso-Gb1; Glucosylsphingosine; Gaucher disease; Biomarker; ENZYME REPLACEMENT THERAPY; VELAGLUCERASE ALPHA; GLUCOSYLSPHINGOSINE; IMIGLUCERASE; MARKERS; PLASMA;
D O I
10.1186/s13023-024-03444-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundPatients with Gaucher disease (GD) require continual monitoring; however, lack of specific disease biomarkers was a significant challenge in the past. Glucosylsphingosine (lyso-Gb1) has been shown to be a reliable, key, specific, and sensitive biomarker for diagnosis, prognosis, and treatment response in clinical studies of patients with GD. We evaluated the change in lyso-Gb1 concentration over time following enzyme replacement therapy in patients with confirmed GD using real-world data from the Gaucher Outcome Survey disease registry.MethodsData for patients aged >= 18 years with a confirmed diagnosis of GD and at least two lyso-Gb1 assessments were analyzed retrospectively. Patients were stratified by treatment status at baseline (time of first lyso-Gb1 assessment). Lyso-Gb1 concentrations were measured from dried blood spot (DBS) samples by Centogene AG. Assessments included change in lyso-Gb1 concentration, hemoglobin concentration, platelet counts, and spleen and liver volume from baseline to the last lyso-Gb1 assessment.ResultsOf 2007 patients enrolled in the Gaucher Outcome Survey as of February 25, 2022, 435 met the inclusion criteria and were included in the study: 318 treated ('all treated'; 277 receiving treatment at baseline, 41 treatment naive at baseline), 38 receiving treatment at baseline who stopped treatment before the last lyso-Gb1 assessment, and 79 untreated. Lyso-Gb1 concentrations decreased from baseline to the last lyso-Gb1 assessment for all treated patients (median change - 8.6 ng/mL), and increased for untreated patients (median change 25.0 ng/mL) and those who stopped treatment (median change 19.5 ng/mL). Decreases were greater for all treatment-naive than previously treated patients (median change - 120.5 vs. - 3.3 ng/mL) and for velaglucerase alfa-treated patients vs. the overall treated cohort (-32.6 vs. - 8.6 ng/mL). Small improvements in hemoglobin concentrations, platelet counts, and spleen volume were observed for treated patients but not untreated/stopped treatment cohorts.ConclusionsIn this study, changes in lyso-Gb1 concentrations from DBS were reflective of responses to enzyme replacement therapy initiation or withdrawal in most patients. These findings confirm that the use of DBS samples for routine monitoring of lyso-Gb1 concentrations in patients with GD is feasible in real-world settings and may be useful to assess treatment response.
引用
收藏
页数:10
相关论文
共 50 条
[41]   Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment [J].
Weinreb, Neal J. ;
Goldblatt, Jack ;
Villalobos, Jacobo ;
Charrow, Joel ;
Cole, J. Alexander ;
Kerstenetzky, Marcelo ;
Dahl, Stephan vom ;
Hollak, Carla .
JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (03) :543-553
[42]   Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States [J].
Abell, Katherine ;
Chadwell, Sarah E. ;
Burrow, Thomas Andrew ;
Becker, Ana Paula Pizzio ;
Bailey, Laurie ;
Steele, Paul ;
Zhang, Xue ;
Islas-Ohlmayer, Miguel ;
Bittencourt, Rosane ;
Schwartz, Ida Vanessa Doederlein ;
Prada, Carlos E. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2020, 184 (04) :1052-1059
[43]   Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: The phase 3 ENGAGE trial [J].
Mistry, Pramod K. ;
Lukina, Elena ;
Ben Turkia, Hadhami ;
Shankar, Suma P. ;
Baris, Hagit ;
Ghosn, Marwan ;
Mehta, Atul ;
Packman, Seymour ;
Pastores, Gregory ;
Petakov, Milan ;
Assouline, Sarit ;
Balwani, Manisha ;
Danda, Sumita ;
Hadjiev, Evgueniy ;
Ortega, Andres ;
Gaemers, Sebastiaan J. M. ;
Tayag, Regina ;
Peterschmitt, M. Judith .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (11) :1170-1176
[44]   A machine learning model for early diagnosis of type 1 Gaucher disease using real-life data [J].
Tenenbaum, Avraham ;
Revel-Vilk, Shoshana ;
Gazit, Sivan ;
Roimi, Michael ;
Gill, Aidan ;
Gilboa, Dafna ;
Paltiel, Ora ;
Manor, Orly ;
Shalev, Varda ;
Chodick, Gabriel .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2024, 175
[45]   Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging [J].
Laudemann, K. ;
Moos, L. ;
Mengel, E. ;
Lollert, A. ;
Hoffmann, C. ;
Brixius-Huth, M. ;
Wagner, D. ;
Dueber, C. ;
Staatz, G. .
BLOOD CELLS MOLECULES AND DISEASES, 2016, 57 :35-41
[46]   Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease [J].
Elstein, Deborah ;
Mehta, Atul ;
Hughes, Derralynn A. ;
Giraldo, Pilar ;
Charrow, Joel ;
Smith, Laurie ;
Shankar, Suma P. ;
Hangartner, Thomas N. ;
Kunes, Yune ;
Wang, Nan ;
Crombez, Eric ;
Zimran, Ari .
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) :592-597
[47]   THE IDENTIFICATION OF TYPE-1 GAUCHER DISEASE PATIENTS, ASYMPTOMATIC CASES AND CARRIERS IN THE NETHERLANDS USING URINE SAMPLES - AN EVALUATION [J].
AERTS, JMFG ;
SAMIRANDA, MC ;
DELACERDA, LW ;
VANWEELY, S ;
DONKERKOOPMAN, W ;
BROUWERKELDER, B ;
JANSEN, DC ;
VANLEEUWEN, M ;
SCHRAM, AW ;
TSIAPARA, A ;
TAGER, JM .
CLINICA CHIMICA ACTA, 1991, 203 (2-3) :349-362
[48]   Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience [J].
Gumus, Ersin ;
Karhan, Asuman Nur ;
Hizarcioglu-Gulsen, Hayriye ;
Demir, Hulya ;
Ozen, Hasan ;
Temizel, Inci Nur Saltik ;
Dokmeci , Serap ;
Yuce, Aysel .
EUROPEAN JOURNAL OF MEDICAL GENETICS, 2021, 64 (11)
[49]   A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration [J].
Peterschmitt, M. Judith ;
Cox, Gerald F. ;
Ibrahim, Jennifer ;
MacDougall, James ;
Underhill, Lisa H. ;
Patel, Palni ;
Gaemers, Sebastiaan J. M. .
BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 :185-191
[50]   Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease [J].
Drelichman, G. ;
Escobar, N. Fernandez ;
Soberon, B. ;
Basack, N. ;
Frabasil, J. ;
Schenone, A. ;
Aguilar, G. ;
Larroude, M. ;
Knight, J. ;
Zhao, D. ;
Ruan, J. ;
Mistry, P. K. .
MOLECULAR GENETICS AND METABOLISM REPORTS, 2021, 29